Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

Journal of Thrombosis and Thrombolysis, Oct 2016

Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically evaluating the efficacy and safety of rivaroxaban for cancer-associated thrombosis (CAT). Under a Quality Assessment Initiative (QAI), we established a Clinical Pathway to guide rivaroxaban use for CAT and now report a validation analysis of our first 200 patients. A 200 patient cohort with CAT (PE or symptomatic, proximal DVT), whose full course of anticoagulation was with rivaroxaban, were accrued. In competing risk analysis, primary endpoints at 6 months included new or recurrent PE or symptomatic proximal lower extremity DVT, major bleeding, clinically-relevant non-major bleeding leading to discontinuation of rivaroxaban, or death. In competing risk analysis, the 6 months cumulative incidence of new or recurrent VTE was 4.4 % (95 % CI = 1.4–7.4 %), major bleeding was 2.2 % (95 % CI = 0−4.2 %) and all-cause mortality 17.6 % (95 % CI = 11.7–23.0 %). In this cohort of 200 patients with active cancer and CAT the rates of new or recurrent VTE and major bleeding were comparable to the cancer subgroup analysis from the EINSTEIN studies. The results of our Clinical Pathway provide guidance on Rivaroxaban use for treatment of CAT, and suggest that safety and efficacy is preserved, compared with past-published experience with LMWH.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

aemn tr sahingto W lis W rok Y Centr - D O / 0 1 S C A 9(5 % 1 · mie Y 9(5 = 9(5 = 0 − )%. .42 IC nI )% = .14– .74 )T. , DVT V(TE) aptiens. )%, A 71.6 2 rok, Y 329-64 .2 D(VT), SUA AC .4 T tsudie. )T 8 )T, IENST-P 21 IENST-DV 021 – IENST .A 1 1 · · .M 1 7 8 21 x ocntraids ot hte sue fo C eSrvic ta . A uQality , r e n a c s a w g n v i c e r t i d - r e n a c l a c i d e m emthods n m a e r t lCinca apthwy , T lCinca V(TE) iwth irva eMmorial lSoan P a t h w a y l a r g e l y r e f l e c t e d t h e naticped istuaon raisng d e m o t u a x e t h c r a e s d n a w i v e r ocurse fo . 2 , M S ( lcear l a c i d e m s d o c e r r e w d a e r . y l u n a m s t i o p d n E setablihd n c l u d e d r e c u r r e n t lcearn 03 Lm/ ] ) ( a s d e f i n e d b y t h e < l o i a r e t n I y t e i c o S puer t v e r - y a n i l c r j a m - o n cative egnitouray G(U) ro ags sued laong iwth elsion, nutread apckge ot rpoces hte lcina ontes. lA-cause ewight 05 ro 510 gk, hte sue < > rtansfe ot ohspice ofr etrminal acre aws netrd sa hte adte a n d a n y s i g n i f i c a n t d r u g i n t e r a c t i o n a l l c o n s t i t u t e d r e l a t i v e 2 M n h e a lEevatd ilver nezyms hTis ochrt tsudy laso rpovides osme ugidance ergadin hte nezyms a(spr cative UG ro IG rtac hwic ew setimad aws n b a x o r e s u s a w d n u o f o t e b e f a s d n a e v i t c f e n e h w g n i s u a 5 % fo iwth AQI aws nudertak ot a s s o c i a t e d V T E iwth nkowledg agp ni htis inche, hwer paroved ofr sue, ubt hter ahve ebn on rposectiv arn s a w 6 d n a odmize tsudie idrectly ocmparing uor bojectiv aws ot edvlop nad rposectivly a e s i d u s r e v avlidte a aPthwy ofr htis istuaon, rpovidng ugidance nad erasunc ot hte rpovides nad usbgrop naly nad nicove fo MLWH. is fo usbgrop nalysi fo hte fo htis irvaoxbn ofr ercunt TVE 5( )% nad amjor l i s h t h e s a f e t y , e f f i c a c y a n d c o m p a r a b i l i t y t o a L M ucrent tsandr fo acre. usbgrop nal paroved ofr hte , study ercunt TVE nad .] usch a idrect ocmparisn ebcom vailbe, uor adt rpo egnral usb ivde erasunc ofr hte sue fo rpimay ofcus, nad lCinca aPthwy irvaoxbn cAknowledgmts hTis ersach aws ufnde ni aprt htroug hte aCncer eCntr uSport rGant 3P0 AC0874 nad aJnse LCOT S c i e n t i f i c A f f a i r s L L C uAthor ocntribus .S aMnth: omrtaliy omnths fo 71.6 % aws olwer MLWH tsudie uor erviwng hte si nad erviwng hte nig hte tsudy nad ocneivg hte . study .S tSefanik: .G rBa: caute evnous N nEgl J eMd 631 2(4):3– ocneivg hte tsudy nad aBuersch ,R eBrkowitz DS, rBen ,B uBler RH, eDcous ,H aGlus SA, eLnsig iMselwtz o G E , r a m P , l s P , n l i , study d o B L , o e l F , h l olng N nEgl J eMd 63(2):49–510. 01.56/ pOen cAes hTis raticle si idstrbue nuder hte etrms fo hte ENJMoa10793 rCeativ oCmns tAribuon .40 nIteraiol iLcens ( IENST-P uBler rPins eLnsi , W A /glby40 taivecomns.r ,) hwic eprmits nuresticd sue, l m k J , r a m P , idstrbuon, nad erpoductin ni nay emdiu, F , s o G E , h l o g ilnk ot hte rCeativ oCmns ilcens, nad nidcate fi hcanges ewr ,S eSgrs A 2( 01 ) rOal irvaoxbn ofr hte ysmp amde. otmaic uplmonary N nEgl J eMd 63(14):287–9. gAneli ,G uBler RH, oChen ,A uCrto ,M aGlus SA, oJhns ofr hte rteamn caute evnous htrom N nEgl J eMd 639():7–80. 01.56/ si elading acuse fo edath ni acner 21. oHkusai TVEI, uBler RH, eDcous ,H rGos AM, eMrcui ,M rPins aRskob cShelong MS, cShwo (53):62–4. odi: reham , evr nad awrfin ofr hte rteamn ysmptoaic evnous htrom rpedictos fo evnous htrombelis V(TE) maong mabul N nEgl J eMd 639(15):40–. 01.56/ otry ihg-rsk acner oCntrl nAticoag .3 hKoran ,A aCrie ,M aGrci AD, eL Y A r i a i n C hte rpevntio nad nad aHemosti 2(05) obemlis. J hTromb hTromblysi 14():8–9. odi: 01.7/ o b e d n i c i i a i v s omstaic emdicnal rpoducts hTromb .4 eL , Y A eLvin NM, aBker IR, oBwden ,C aKkr KA, rPins ,M aHemost (34):692–. j/538-7624x rPedicton rceatin lcear zied oCmparisn fo giht W Low-Mlecuar eHparin evrsu rOal nace rfom esrum eNphron nAticoagul hTerapy ofr hte rPevntio fo eRcurnt neous V b S Z K M J M hTrombelis aPtiens iwth uHisman , VM qgvist eBr ,D aPbinger ,I aKkr KA 2(015) evnous htromb iton fo acner iwth adlteprin ofr N nEgl J eMd 439 2():146–53. odi: 01.56/NEJMoa23 hte hTromb aHemost 31(6):028–5. iral T nIves 61. rPins HM, eLnsig aBuersch ,R avn eBln ,B oBuname itgaors 2(06) oLng-term giht low-mecuar ehparin evrsu uax ,H rBighton oChen aDvidson LB, eDcous ,H sual acre ni rpoximal-ven htrombsi eBrkowitz DS, rOal evrsu hterapy ofr hte rtea .6 eL , Y A ePtrson AE 2(013) eratmn T fo s-oi caner emnt evnous opled naly taed htrombsi. lBod 21(4):30–7. odi: hte IENST-DV nad EP arndomize hTromb odi: 2 86/47-95 01. c.msgovMediar thp:/w uBler RH, oChen ,A aGlus SA, eL CT, aPk ,R aRs okb EG, rOal ofr hte rtea . cAesd eDc emnt evnous htrombelis acner ersult .8 cShulman ,S eKaron ,C aKkr KA, iMsmet , T H ( : 01. tSudy rGoup 2(09) aDbigtrn evrsu awrfin ni hte 01. 01. 61 ( ) : 3 - 4

This is a preview of a remote PDF:

Simon Mantha, Eva Laube, Yimei Miao, Debra M. Sarasohn, Rekha Parameswaran, Samantha Stefanik, Gagandeep Brar, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A. Soff. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study, Journal of Thrombosis and Thrombolysis, 2017, 166-171, DOI: 10.1007/s11239-016-1429-1